The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Larson Financial Group LLC cut its holdings in GSK plc (NYSE:GSK – Free Report) by 52.7% during the fourth quarter, according ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 ...

Atria Investments Inc cut its holdings in GSK plc (NYSE:GSK – Free Report) by 7.6% in the fourth quarter, according to the ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

Group sales fell 4 per cent to £5.6 billion ... falling 12 per cent to a little over £1.09 billion and down 19 per cent in the US. GSK chief executive Andrew Witty told investors yesterday ...

GSK's revenue and EPS exceeded my expectations ... it was approved by the U.S. health regulator for the treatment of a specific group of adolescents over 12 years of age with HIV-1 infection ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.